We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potential over the next 12 months.Is AbCellera Biologics Inc. (ABCL) the Best Multibagger Stocks to Invest in Now

A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform.

AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody discovery. Founded in 2012, the company integrates cutting-edge technology, advanced data science techniques, and interdisciplinary expertise to streamline the development of innovative antibody medicines. These medicines target a range of health issues, including cancer, autoimmune disorders, and metabolic conditions, addressing critical therapeutic needs in the biopharmaceutical landscape. AbCellera's pipeline includes promising candidates such as ABCL635, designed to tackle metabolic and endocrine conditions, and ABCL575, which is focused on treating T-cell-mediated autoimmune conditions like atopic dermatitis. Both programs remain in preclinical stages, with Clinical Trial Applications expected to commence by 2025, a milestone that underscores AbCellera's commitment to advancing its pipeline with precision and speed.

AbCellera's success has been bolstered by strategic collaborations with industry giants such as Eli Lilly, Biogen, and AbbVie. These partnerships have enabled the company to leverage partner insights, cutting-edge technologies, and shared expertise to develop highly optimized clinical candidates. Since its inception, AbCellera has initiated an impressive 96 partner programs, with 16 molecules having reached clinical trials, a testament to the effectiveness of its unique platform. The company's focus extends beyond partnerships, as it has heavily invested in its research infrastructure. By the end of 2025, AbCellera aims to complete its clinical manufacturing facilities, a significant step that will position the company to efficiently bring next-generation antibody therapeutics to market while maintaining high standards of innovation and quality.

In terms of financial performance, AbCellera Biologics Inc. (NASDAQ:ABCL) demonstrated a solid topline of $4.24 million for the first quarter of 2025, bolstered by milestone payments and antibody discovery collaborations. For the full year 2024, the company reported a topline of $28.8 million, further solidifying its financial robustness. With a substantial cash position of $540 million, AbCellera is well-equipped to sustain its growth trajectory. On 15th May, 2025, analysts downgraded their estimates based on revenue estimates being lower than expectations. Overall, however, analysts remain optimistic about the stock, highlighting an average share price projection of $11.43 over the next twelve months, presenting an upside potential of 474.37%.

Story Continues

Overall, AbCellera Biologics Inc. (NASDAQ:ABCL) ranks 7th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.

View Comments